Skip to main content
← News ENFR SearchSubscribe

No single capital owns the whole truth

The Wire

Laprophan’s Casablanca listing draws $1.5 billion of orders; seven times the shares on offer

Morocco’s largest listing of the year: 44,000 investors sought shares in the drugmaker Laprophan, whose 2.22 billion-dirham IPO will fund the Polymedic acquisition. Shares start trading on 25 November.

A busy street in Casablanca, Morocco, home of the Casablanca Stock Exchange where Laprophan is listing.
Casablanca, home of the Casablanca Stock Exchange. Laprophan’s listing is the market’s largest of 2026.AndrewEick, CC BY 2.0, via Wikimedia Commons

Key points

  • Demand: Investors submitted orders worth 15.3 billion dirhams (about $1.5 billion) for Laprophan shares, roughly seven times the 2.22 billion dirhams on offer, with about 44,000 subscribers. 1
  • Offer: Laprophan sold 6,517,700 shares at 341 dirhams each, 4,105,500 new shares and 2,412,200 existing shares, valuing the company at about 5.9 billion dirhams. 2
  • Timetable: Subscriptions ran from 9 to 17 November; shares are allocated on 23 November and start trading on 25 November, when the final results are formally announced. 6
  • Purpose: The proceeds are intended to fund the acquisition of Polymedic, a rival Moroccan drugmaker that generated revenue of about 405 million dirhams in 2025, pending approval from the Competition Council. 1
  • Company: Founded in 1949, Laprophan operates four industrial sites in Morocco and Switzerland and reported revenue of 1.82 billion dirhams in 2025, up from 1.64 billion a year earlier. 1

ONE EVENT. THREE READINGS.

West

In the Western reporting, the story is a numbers story with a continental superlative.

Reuters leads with the multiple, seven times oversubscribed, and the $1.5 billion of orders.

What this reading highlights: Bloomberg, via Moneyweb, leads with the record: the largest pharmaceutical IPO in Africa, the second-largest private Moroccan listing.

The frame is the market: demand, valuation, ranking. Both agencies quote the same source, the lead manager CFG Bank, and both treat the listing as a capital-markets event first and a Moroccan event second.

Sources: Reuters (1), Bloomberg via Moneyweb (1), Dealroom (1)

East

No independent East Asian reporting on the listing was found at the time of writing.

Neither CNA, The Hindu, NHK nor Kyodo covered the subscription result, and a general search returned no East-outlet account.

What this reading highlights: The only Asia-facing coverage is Asharq Business, Bloomberg’s Arabic-language service, which reports the same figures with a Gulf investor’s eye.

The absence is itself the finding: a Moroccan domestic listing, however large, barely registers in East Asian financial press.

Global South

In the Southern press, the story is a domestic event with a caution attached.

La Vie Eco and Hespress report the same numbers, 15.3 billion dirhams, 44,000 subscribers, but Hespress pairs the IPO boom with the market’s weakness: the MASI down, volumes halved, and T2S trading below its offer price after a 43.75-times subscription.

What this reading highlights: Radarr Africa, writing from the continent’s capital-markets angle, stresses the deal’s structure and the Polymedic acquisition.

The Southern reading is pride in the record, tempered by the question of what happens after the debut.

Sources: La Vie Eco (1), Hespress (1), Morocco World News (1), Radarr Africa (1), Asharq Business (1), IPO Maroc (1)

Sources by lens: 3 West, 0 East, 6 Global South. See every source

THE POINT OF CONVERGENCE

On the facts. Investors ordered 15.3 billion dirhams of Laprophan shares against a 2.22 billion-dirham offer, with about 44,000 subscribers; the shares were priced at 341 dirhams, subscriptions ran from 9 to 17 November, and trading begins on 25 November. Every independent outlet reporting the result gives the same figures.

WHAT REMAINS CONTESTED

On what the demand means. The lead manager’s final estimates put the offer at seven times oversubscribed; Bloomberg, citing the same manager earlier in the day, put it at six. The gap is a matter of preliminary versus final tallies, and the formal results on 25 November will settle it.

The story

44,000 investors chase a Casablanca listing seven times over

Investors sought 15.3 billion dirhams (about $1.5 billion) of shares in Moroccan drugmaker Laprophan, roughly seven times the 2.22 billion dirhams on offer, according to final estimates from CFG Bank, the listing’s lead manager. About 44,000 subscribers took part in the subscription, which closed on 17 November.

The result, reported by Reuters on Thursday evening, makes Laprophan the largest listing on the Casablanca Stock Exchange this year and, on Bloomberg-compiled data, the largest pharmaceutical flotation Africa has ever seen. Shares are allocated on 23 November and start trading on 25 November, when the final results are formally announced.

The listing is the third on the Casablanca exchange in 2026, after medical-technology group T2S and renewable-energy company Jet Energy; and by far the biggest of the three.

Advertisement

Why did 44,000 investors pile into one drugmaker?

Laprophan offered 6,517,700 shares at 341 dirhams each, valuing the company at about 5.9 billion dirhams. The offer mixes 4,105,500 new shares, raising about 1.4 billion dirhams of fresh capital, with 2,412,200 existing shares sold by funds managed by Mediterrania Capital Partners. The shares on offer represent 37.6 percent of the company’s capital.

The money has a named destination. Laprophan plans to use the proceeds to buy Polymedic, a rival Moroccan drugmaker, in a deal signed in October for the whole of Corporate Investment Holding, Polymedic’s parent, pending approval from Morocco’s Competition Council. Polymedic generated revenue of about 405 million dirhams in 2025.

The company itself is no startup. Founded in 1949, Laprophan runs four industrial sites in Morocco and Switzerland and reported revenue of 1.82 billion dirhams in 2025, up from 1.64 billion a year earlier. Morocco’s capital-markets regulator, the AMMC, approved the prospectus on 28 October.

The demand was unevenly spread. Institutional investors in the first tranche ordered 14.4 billion dirhams of shares, nine times their allocation; retail investors in the second tranche ordered 800 million dirhams, 1.6 times theirs. A third tranche, 5.1 percent of the offer, was reserved for employees at a discounted 273 dirhams a share.

The timetable is fixed: allocations go to intermediaries on 23 November, the final results are published and trading begins on 25 November under the ticker LPH on the exchange’s main compartment.

What does seven times oversubscribed actually mean?

First, the multiple itself is not yet final. Bloomberg, citing the same lead manager earlier on Thursday, put the oversubscription at six times; the seven-times figure is the final estimate reported in the evening. The hard numbers, 15.3 billion dirhams of orders against a 2.22 billion-dirham offer, imply 6.9 times. The formal results on 25 November will settle it.

Second, nobody knows yet what each investor will actually receive. Institutions ordered nine times their tranche and will be scaled back sharply; retail subscribers ordered 1.6 times theirs and should receive most of what they asked for. The allocation key is published on 23 November.

Third, the Polymedic acquisition is not done. The deal still needs the Competition Council’s approval, and the prospectus does not say what happens to the timetable if approval slips.

A record drug listing tests a market that is booming and shrinking at once

By Bloomberg’s count this is the largest pharmaceutical IPO in African history and the second-largest listing by a private Moroccan company, after SGTM in 2025. On Asharq Business’s count it is the fifth-largest listing in the Casablanca market’s history. Either way, it is a landmark for a market with only 82 listed companies and a stated ambition to reach 300 by 2035.

It also lands in a contradictory market. Casablanca’s IPO window is wide open, T2S drew 48.13 billion dirhams of orders, 43.75 times its offer, from more than 111,000 investors; Jet Energy was 31.4 times covered, yet the MASI index is down 12.25 percent since January and October trading volumes fell 54.7 percent year on year. Investors are hungry for new paper and cool on old paper at the same time.

For Morocco, the listing is part of a wider industrial push. Days earlier, the Kingdom launched the Morocco Offer, a roadmap to build a domestic defence industry, and signed a security pact with the UAE; the same logic of turning manufacturing strength into listed, exportable champions, applied here to pharmaceuticals.

Why are institutions and small investors reading this listing differently?

Read the two tranches and you read two different bets. Institutions ordered nine times their allocation; retail investors, 1.6 times. The institutions are buying the Africa’s-largest-pharma-IPO story and a scarce asset in a thin market; the crowd is buying a household name at a fixed price, in smaller tickets, with less urgency.

That split is the honest frame for the whole operation. A seven-times headline flatters the deal; the retail multiple, 1.6 times, is the more grounded measure of public enthusiasm. And as financial analyst Hassan Belghazi told Hespress, heavy IPO subscriptions do not necessarily mean fresh, lasting investment: investors often shift money out of existing shares to chase a new listing’s quick gain.

The precedents warn in the same direction. T2S, the year’s first IPO, was 43.75 times oversubscribed and its shares jumped nearly 20 percent on debut; then fell below the offer price. Jet Energy, 31.4 times covered, also debuted strongly. The pattern in Casablanca this year is a hot subscription, a warm debut, and then the market’s judgement.

What would change the reading is the Polymedic deal. If the acquisition closes, Laprophan becomes a consolidator with a bigger domestic base and a stated international expansion plan; a company story, not just a listing story. If it stalls at the Competition Council, the proceeds sit and the growth case thins.

Through the Bureau’s 5D lens, the listing is three stories at once: economics, as Morocco deepens a capital market that must fund its industrial ambitions; the same logic behind its defence of its car industry against new European rules; geopolitics, as a Moroccan drugmaker builds the scale to supply African markets rather than import from them; and demographics, as 44,000 subscribers, overwhelmingly Moroccan savers, take a direct stake in that bet.

The second wave: allocations, the debut, and the Polymedic file

Three dates decide the next chapter. Allocations reach intermediaries on 23 November; the first trade and the formal results land on 25 November. Watch the opening price against 341 dirhams, and whether it holds through the first week; T2S did not. Then comes the Competition Council’s ruling on Polymedic, which decides whether the proceeds buy growth or sit idle. A clean debut plus a cleared acquisition would put other Moroccan groups on the path to the market; the exchange’s own target is 300 listed companies by 2035, against 82 today. A weak debut would cool the pipeline fast.

What should investors watch on 25 November?

First, the allocation key on 23 November: how much of each order was filled, and whether retail subscribers, who ordered 1.6 times their tranche, were treated better than institutions, who ordered nine times theirs. Second, the debut itself on 25 November: the opening price, the volume, and the formal results that confirm the final multiple; six times or seven. Third, the Competition Council’s decision on Polymedic, the deal the whole operation is meant to fund. The listing is a success on paper already; the next two weeks decide whether it is a success in the market.

Longer term, the test is whether Laprophan uses the listing the way its prospectus promises, to buy Polymedic, broaden its range and expand internationally, or whether it joins T2S as a hot subscription that faded on the screen.

What we agree on, and what remains open

Established

  • On the facts. Investors ordered 15.3 billion dirhams of Laprophan shares against a 2.22 billion-dirham offer, with about 44,000 subscribers.
  • The shares were priced at 341 dirhams, subscriptions ran from 9 to 17 November, and trading begins on 25 November. Every independent outlet reporting the result gives the same figures.

Contested

  • On what the demand means. The lead manager’s final estimates put the offer at seven times oversubscribed.
  • Bloomberg, citing the same manager earlier in the day, put it at six. The gap is a matter of preliminary versus final tallies, and the formal results on 25 November will settle it.

Still open

  • Whether the debut will hold. T2S, the year’s first IPO, was 43.75 times oversubscribed and still fell below its offer price after a strong debut, while October trading volumes fell 54.7 percent year on year. Nor do we know whether the Competition Council will clear the Polymedic deal.

What to watch

We expect: the allocation key, the first trade and formal results on 25 November, and the Competition Council’s ruling on Polymedic to decide whether this record subscription becomes a durable listing; and whether other Moroccan companies follow Laprophan to the market.

Questions, answered

Laprophan is a Moroccan pharmaceutical group founded in 1949, with four industrial sites in Morocco and Switzerland and revenue of 1.82 billion dirhams in 2025. Its 2.22 billion-dirham listing is the largest on the Casablanca Stock Exchange this year and, on Bloomberg-compiled data, the largest pharmaceutical IPO ever in Africa.

Sources by lens

West (3)
1Reuters(19 Nov 2026)
7Dealroom(19 Nov 2026)
Global South (6)
3La Vie Eco(18 Nov 2026)
4Hespress(13 Nov 2026)
5Morocco World News(29 Oct 2026)
6Radarr Africa(19 Nov 2026)
8Asharq Business(19 Nov 2026)
9IPO Maroc(18 Nov 2026)

Open access ends December 31 — from January 1, 2027, the depth is for members.

See membership